Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jay Pandhi

Interventional Cardiology National City, CA Medical Doctor

NPI 1407997406 CMS profile 200314

655 Euclid Ave, Suite 208, National City, CA 91950

Open in the dashboard

General payments

$523

23 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jay Pandhi of National City, CA is reported in the CMS Open Payments database as having received $523 across 23 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 8th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $85 3
2022 General $108 5
2021 General $119 5
2020 General $18 1
2019 General $194 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jay Pandhi
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Jay Pandhi were reported at $85. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Jay Pandhi Interventional Cardiology median Middle half National median
2019 $194 $1,097 $329–$3,048 $163
2020 $18 $473 $161–$1,480 $114
2021 $119 $677 $233–$1,827 $132
2022 $108 $978 $333–$2,724 $149
2023 $0 $1,136 $382–$2,986 $160
2024 $0 $1,181 $395–$3,326 $164
2025 $85 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $86 1 payment
  2. Novartis Pharmaceuticals Corporation $86 5 payments
  3. Boston Scientific Corporation $74 3 payments
  4. Medtronic Vascular, Inc. $53 3 payments
  5. Shockwave Medical, Inc $47 2 payments
  6. Stryker Corporation $44 1 payment
  7. Acist Medical Systems, Inc. $42 2 payments
  8. Philips Electronics North America Corporation $36 2 payments
  9. Kestra Medical Technology Services, Inc. $25 1 payment
  10. bioMerieux $15 1 payment
  11. Other $16 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $523 23 payments
Products named General payments · program years 2019–2025
  1. TRULICITY $86 1 payment
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $47 2 payments
  3. ENTRESTO $45 3 payments
  4. FLOWTRIEVER $44 1 payment
  5. LEQVIO $41 2 payments
  6. Resolute $32 2 payments
  7. RXi Systems $30 1 payment
  8. POLARIS $25 1 payment
  9. Assure WCD $25 1 payment
  10. ROTABLATOR $25 1 payment
  11. Other $124 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

522

Median for Cardiology: 2,533

Drug cost

$141,397

Median for Cardiology: $485,213

Branded share of claims

36.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 158 $137,825
Metoprolol Succinate Generic 55 $879
Amlodipine Besylate Generic 81 $525
Losartan Potassium Generic 42 $445
Carvedilol Generic 39 $356
Atorvastatin Calcium Generic 31 $299
Clopidogrel Clopidogrel Bisulfate Brand 22 $287
Telmisartan Generic 13 $230
Lisinopril Generic 17 $162
Metoprolol Tartrate Generic 15 $135

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$134,230

Of which drugs: $231

Medicare patients

342

Average age 76

Services billed

2,508

186 women, 156 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 65%
Chronic kidney disease 51%
Heart failure 50%
Ischemic heart disease 47%
Arthritis 43%
Atrial fibrillation 35%
Depression 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 12 48 $231

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

23 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record